Although CD19-directed CAR T cells can initially induce remission in 70-90% of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), post-CAR relapses are frequent. These ...

CAR T cells engineered to secrete the TIM-3 decoy showed improved anti-leukemia effectiveness and ... A TIM-3-Fc decoy secreted by engineered T cells improves CD19 CAR-T cell therapy in B-cell ...

Explore the impact of functional respiratory tests on outcomes in anti-CD19 CAR T-cell therapy, presented at EBMT 2025.

In the case of systemic lupus erythematosus, clinical trials have demonstrated that anti-CD19 CAR T cells are effective in eliminating pathogenic B cells, with sustained remissions in 80% of ...

Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing ...

Discover the long-term results of CAR T-cell therapy, with and without stem cell transplantation, for relapsed lymphoma ...

Axi-cel, tisa-cel, and brexu-cel were found comparable to other cellular therapy experiences for patients with B-cell ...

Renier Brentjens, a CAR T-cell pioneer, views armored CAR T-cells as a promising avenue for treating solid tumors and ...

Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy in 9 patients with 78% having objective responses, ...

Reports FY24 revenue $6.59M, consensus $8.32M. “In 2024, we made substantial progress advancing MT-601, our lead multi antigen recognizing-T ...

CAR-T cells engineered to secrete the TIM-3 decoy showed improved anti-leukemia effectiveness and long-term persistence. Although still in the preclinical stage, this research marks an important ...